454 related articles for article (PubMed ID: 27705910)
1. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
Schafer CC; Wang Y; Hough KP; Sawant A; Grant SC; Thannickal VJ; Zmijewski J; Ponnazhagan S; Deshane JS
Oncotarget; 2016 Nov; 7(46):75407-75424. PubMed ID: 27705910
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Li F; Zhao Y; Wei L; Li S; Liu J
Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2, 3-Dioxygenase Promotes Aryl Hydrocarbon Receptor-Dependent Differentiation Of Regulatory B Cells in Lung Cancer.
Tousif S; Wang Y; Jackson J; Hough KP; Strenkowski JG; Athar M; Thannickal VJ; McCusker RH; Ponnazhagan S; Deshane JS
Front Immunol; 2021; 12():747780. PubMed ID: 34867973
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.
Thorn M; Guha P; Cunetta M; Espat NJ; Miller G; Junghans RP; Katz SC
Cancer Gene Ther; 2016 Jun; 23(6):188-98. PubMed ID: 27199222
[TBL] [Abstract][Full Text] [Related]
5. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
Holmgaard RB; Zamarin D; Lesokhin A; Merghoub T; Wolchok JD
EBioMedicine; 2016 Apr; 6():50-58. PubMed ID: 27211548
[TBL] [Abstract][Full Text] [Related]
6. CARD9 prevents lung cancer development by suppressing the expansion of myeloid-derived suppressor cells and IDO production.
Qu J; Liu L; Xu Q; Ren J; Xu Z; Dou H; Shen S; Hou Y; Mou Y; Wang T
Int J Cancer; 2019 Oct; 145(8):2225-2237. PubMed ID: 31008530
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway.
Li R; Li H; Sun Q; Liu L; Zhang C; Ren X
Mol Immunol; 2017 Jan; 81():102-107. PubMed ID: 27930920
[TBL] [Abstract][Full Text] [Related]
8. Ganoderma lucidum polysaccharide (GLP) enhances antitumor immune response by regulating differentiation and inhibition of MDSCs via a CARD9-NF-κB-IDO pathway.
Wang Y; Fan X; Wu X
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32530032
[TBL] [Abstract][Full Text] [Related]
9. STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.
Lemos H; Mohamed E; Huang L; Ou R; Pacholczyk G; Arbab AS; Munn D; Mellor AL
Cancer Res; 2016 Apr; 76(8):2076-81. PubMed ID: 26964621
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
11. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2,3-dioxygenase increases p53 levels in alloreactive human T cells, and both indoleamine 2,3-dioxygenase and p53 suppress glucose uptake, glycolysis and proliferation.
Eleftheriadis T; Pissas G; Antoniadi G; Spanoulis A; Liakopoulos V; Stefanidis I
Int Immunol; 2014 Dec; 26(12):673-84. PubMed ID: 25064493
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells.
Eleftheriadis T; Pissas G; Antoniadi G; Liakopoulos V; Stefanidis I
Immunology; 2015 Oct; 146(2):292-300. PubMed ID: 26147366
[TBL] [Abstract][Full Text] [Related]
15. Role of indoleamine 2,3-dioxygenase in acute myeloid leukemia.
Sobash PT; Kolhe R; Karim NA; Guddati AK; Jillella A; Kota V
Future Oncol; 2020 Dec; 16(36):3085-3094. PubMed ID: 32976029
[TBL] [Abstract][Full Text] [Related]
16. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X
Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334
[TBL] [Abstract][Full Text] [Related]
17. Tumor-Targeted Gene Silencing IDO Synergizes PTT-Induced Apoptosis and Enhances Anti-tumor Immunity.
Zhang Y; Feng Y; Huang Y; Wang Y; Qiu L; Liu Y; Peng S; Li R; Kuang N; Shi Q; Shi Y; Chen Y; Joshi R; Wang Z; Yuan K; Min W
Front Immunol; 2020; 11():968. PubMed ID: 32582152
[No Abstract] [Full Text] [Related]
18. Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity.
Yang J; Yan C; Vilgelm AE; Chen SC; Ayers GD; Johnson CA; Richmond A
Cancer Immunol Res; 2021 Feb; 9(2):200-213. PubMed ID: 33177110
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
Ito H; Ando T; Arioka Y; Saito K; Seishima M
Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of indoleamine 2,3-dioxygenase in mixed lymphocyte reaction affects glucose influx and enzymes involved in aerobic glycolysis and glutaminolysis in alloreactive T-cells.
Eleftheriadis T; Pissas G; Yiannaki E; Markala D; Arampatzis S; Antoniadi G; Liakopoulos V; Stefanidis I
Hum Immunol; 2013 Dec; 74(12):1501-9. PubMed ID: 23993986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
